Amgen Stock Firms Up After Q2 Earnings Beat

Amgen Inc.'s (US0311621009) stock remained steady after its Q2 2026 earnings beat, reporting revenue of $10.05 billion and adjusted EPS of $6.29 for the quarter ended June 30, 2026.

The company's shares opened at $436.99 in the latest session and traded near a one-year high of $447.03.

Amgen's Q2 2026 revenue rose 9.5% from the same period last year, while its adjusted EPS improved from $6.02, indicating continued growth in its core business.

The company has also lifted its FY 2026 guidance to $22.30-$23.50 per share, which is slightly above analysts' consensus figure of $22.92.